American Well Co. (NYSE:AMWL) Receives Consensus Rating of “Hold” from Brokerages

American Well Co. (NYSE:AMWL) has been assigned an average rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $11.90.

A number of equities research analysts have commented on the company. Morgan Stanley decreased their price objective on American Well from $20.00 to $10.50 and set an “equal weight” rating for the company in a research report on Tuesday, December 17th. Needham & Company LLC restated a “hold” rating on shares of American Well in a research report on Thursday, February 13th. Stifel Nicolaus raised their price objective on American Well from $9.00 to $10.00 and gave the stock a “hold” rating in a research report on Thursday, February 13th. Truist Financial lifted their price target on American Well from $10.00 to $12.00 and gave the company a “hold” rating in a report on Friday, February 14th. Finally, Wells Fargo & Company upgraded American Well from an “equal weight” rating to an “overweight” rating and set a $15.00 price target for the company in a report on Monday, January 13th.

American Well Stock Up 1.3 %

NYSE:AMWL opened at $7.99 on Tuesday. American Well has a 1-year low of $5.00 and a 1-year high of $18.80. The firm has a market capitalization of $124.72 million, a price-to-earnings ratio of -0.57 and a beta of 1.18. The stock has a fifty day simple moving average of $9.96 and a 200 day simple moving average of $9.31.

American Well (NYSE:AMWL) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($2.77) EPS for the quarter, topping analysts’ consensus estimates of ($3.04) by $0.27. American Well had a negative return on equity of 56.73% and a negative net margin of 81.83%. Equities analysts predict that American Well will post -9.34 earnings per share for the current year.

Insider Activity at American Well

In related news, insider Phyllis Gotlib sold 4,781 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.80, for a total value of $42,072.80. Following the transaction, the insider now directly owns 147,998 shares of the company’s stock, valued at approximately $1,302,382.40. This trade represents a 3.13 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders have sold 5,219 shares of company stock valued at $46,454. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Two Sigma Investments LP raised its stake in shares of American Well by 12.3% in the 4th quarter. Two Sigma Investments LP now owns 19,216 shares of the company’s stock valued at $139,000 after acquiring an additional 2,102 shares in the last quarter. Two Sigma Advisers LP increased its position in American Well by 102.7% in the 4th quarter. Two Sigma Advisers LP now owns 41,045 shares of the company’s stock worth $298,000 after buying an additional 20,800 shares during the period. OMERS ADMINISTRATION Corp bought a new position in American Well in the 4th quarter worth approximately $76,000. Corton Capital Inc. bought a new position in American Well in the 4th quarter worth approximately $134,000. Finally, Bridgeway Capital Management LLC increased its position in American Well by 39.4% in the 4th quarter. Bridgeway Capital Management LLC now owns 96,741 shares of the company’s stock worth $701,000 after buying an additional 27,343 shares during the period. 56.05% of the stock is owned by institutional investors.

About American Well

American Well Corporation, an enterprise platform and software company, delivers digitally enabling hybrid care in the United States and internationally. The company offers Converge, a cloud-based platform that enables health providers, payers, and innovators to provide in-person, virtual and automated care; and delivers virtual primary care, post-discharge follow-up, chronic condition management, virtual nursing, e-sitting, on-demand and scheduled virtual visits, specialty consults, automated care, and behavioral health, as well as specialty care programs, including dermatology, musculoskeletal care, second opinion, and cardiometabolic care to patients and members.